Longevity Biotech, Inc. logo

Longevity Biotech, Inc.

We are developing new therapeutics drugs based on the Hybridtide platform technology.
Longevity Biotech Inc. is a preclinical biotechnology company focused on developing therapeutics for the treatment of nerological disorders such as Parkinsons disease and Multiple Sclerosis.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://longevitybiotech.com
Founded2010
Disease Focus
Development StagePreclinical
STOCK CODENon Listed
Address
3025 Market Street, Suite 140,PA,19104,
Philadelphia
United States
Email
Contact Number
+1 215-689-1042

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/longevity-biotech” connections=”true” suffix=””]

Longevity Biotech Inc. is a preclinical biotechnology company focused on developing therapeutics for the treatment of nerological disorders such as Parkinsons disease and Multiple Sclerosis.

Jan 2018, Longevity Biotech Inc. (LBT) has been awarded $225K Phase I SBIR Contract From NHLBI/NIH to Develop 5A apoA-I Mimetic Peptide for Treatment of Severe Asthma.

In Oct 2017, Longevity Biotech Awarded Grant from National Multiple Sclerosis Society to Evaluate LBT-3627 as a Novel Drug Candidate for Multiple Sclerosis.

Feb 2017, Longevity Biotech and University of Nebraska Medical Center Awarded Continuing Grant from the Michael J. Fox Foundation for Furthers development of LBT-3627 focusing on immunomodulatory therapeutic strategy to treat Parkinsons disease

In May 2015, Longevity Biotech was awarded research grant from Micheal J. Fox Foundation to determine key mechanisms and safety of a Parkinsons disease therapeutic drug candidate.

Longevity has received more than $600K in 2 Rounds from its investors Thiel Foundation, Breakout Labs and National Science Foundation (NSF).